Integer Holdings (ITGR) Stock Forecast & Price Target

Integer Holdings is supported by a durable medtech franchise that still delivered a Q1 sales beat of $440M and adjusted EPS of $1.20 despite softer gross and operating margins, underscoring resilient demand across both C&V and Cardiac & Neuro. Management’s explanation that the full-year guide reduction reflects one-time customer forecast resets in select EP accessories, not structural weakness, is important because the core EP market remains strong with high-teens growth. The strategic review following heightened inbound interest also signals that investors may be underappreciating Integer’s attractive valuation, improving business quality, and ability to recover as market stabilization unfolds.

Integer Holdings is facing a weaker near-term fundamental backdrop, with 3Q26E revenue expected to fall 3.7% year over year to $450.5 million and adjusted EPS to slip to $1.63 from $1.79, while full-year 2026E sales are projected at $1.816 billion, down 2% from 2025. The downside is being driven by lower gross margins, higher overhead from recent operational investments, and reduced guidance after customer forecast updates and softer market dynamics cut midpoint revenue by $31 million, adjusted operating income by $19 million, and adjusted EPS by $0.42. Although 2Q26 revenues of $464.1 million were only down 2.6%, the mix remained pressured by a 2% decline in Cardio & Vascular and lower Other Markets sales, and the pending KKR sale limits visibility and adds transaction-related uncertainty.